Dianthus Therapeutics Inc... (DNTH)

NasdaqCM: DNTH · Real-Time Price · USD

109.51

-4.19 (-3.69%)

At close: Aug 20, 2026, 3:59 PM

109.01

-0.46%

Pre-market: 7:08 AM

The price, the headline numbers and the latest news, in one place.

-3.69% (1D)

Bid	80.64
Market Cap	6.13B
Revenue (ttm)	1.9M
Net Income (ttm)	-192.25M
	0.08
	-4.09
	n/a
	-23.09
P/B (ttm)	5.12
P/S (ttm)	3144.17
Earnings Date	Nov 5, 2026

Ask	141.9
Volume	735,467
Avg. Volume (20D)	1,061,974
Open	111.73
Previous Close	113.70
Day's Range	107.36 - 112.68
52-Week Range	22.76 - 117.88
Analyst	n/a
Price Target	n/a
Dividends	n/a
Ex-Dividend Date	n/a

About DNTH

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Jun 21, 2018

Employees 92

Stock Exchange NasdaqCM

Ticker Symbol DNTH

Website https://dianthustx.com

Full Company Profile

Financial Performance

In 2025, Dianthus Therapeutics's revenue was 2.04M, a decrease of -67.35% compared to the previous year's 6.24M. Earnings were -162.34M, an increase of 91.05%.

Financial Statements

Earnings Surprise

Dianthus Therapeutics has released their quarterly earnings on Aug 4, 2026:

Revenue of $761K misses estimates by $0, with 294.30% YoY growth.

EPS of -0.9 exceeds estimates by 0.01, with -2.27% YoY decline.

Next Earnings Release

Dianthus Therapeutics Inc. is scheduled to release its earnings on Nov 5, 2026, during market hours.
Analysts project revenue of ... Upgrade

News

2 weeks ago · Zacks

Dianthus Therapeutics, Inc. (DNTH) Reports Q2 Loss, Tops Revenue Estimates

Dianthus Therapeutics, Inc. (DNTH) delivered earnings and revenue surprises of +3.23% and +60.89%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the s...

2 months ago · Zacks

DNTH Shares Surge 89% Over the Past Six Months: What's Driving It?

Dianthus Therapeutics stock climbs 89% in six months as claseprubart advances across key autoimmune studies. Strong cash position supports development into 2030.

2 months ago · Simply Wall St.

Dianthus CIDP Data Lift Prospects While Funding And Dilution Risks Linger

Dianthus Therapeutics reported a 75% response rate in a late-stage trial of claseprubart in CIDP. The update comes shortly after Sanofi discontinued a similar CIDP trial, leaving fewer competitors in ...